MUMBAI, India, May 29 -- Intellectual Property India has published a patent application (202621050311 A) filed by Dr. Sumeet Dwivedi; Prof. Kanchan Ashish Mahajan; Dr. Prerna Chaturvedi; Prof. Surekha Abhay Patil; Mrs. Pradnya Ghanshyam Patil; Prof. Shital Jayesh Gandhi; and Ms. Chaitali Pravin Jaiswal, Indore, Madhya Pradesh, on April 20, for 'niosomal gel of nigella sativa seed extract for atopic dermatitis treatment.'
Inventor(s) include Dr. Sumeet Dwivedi; Prof. Kanchan Ashish Mahajan; Dr. Prerna Chaturvedi; Prof. Surekha Abhay Patil; Mrs. Pradnya Ghanshyam Patil; Prof. Shital Jayesh Gandhi; and Ms. Chaitali Pravin Jaiswal.
The application for the patent was published on May 29, under issue no. 22/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a niosomal gel formulation comprising a hydroalcoholic extract of Nigella sativa seeds encapsulated within non-ionic surfactant-cholesterol vesicles and incorporated into a carbopol 934-based gel matrix for topical treatment of atopic dermatitis. Niosomes are prepared by thin-film hydration using Span 60 or Tween 60 and cholesterol; the optimized formulation F3 (Span 60: 100 mg, cholesterol: 100 mg) exhibits vesicle size 180 nm, entrapment efficiency 85%, zeta potential -32 mV, and 90% drug release over 24 hours. The niosomal gel demonstrates pH 6.5, viscosity 4500 to 5200 cP, drug content 95 to 98%, and ex vivo permeation of 88%, significantly superior to conventional herbal gel. In vivo studies in a DNCB-induced mouse model confirm significant reduction in SCORAD index and serum IgE levels, establishing the formulation as a safe, efficacious, and corticosteroid-free herbal nanomedicine alternative for atopic dermatitis management with potential for commercialization."
Disclaimer: Curated by HT Syndication.
